Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 9 of 9 for “"CDK4/6 inhibitors"”.
-
Targeting Autophagy to Improve Efficacy of Cdk4/6 Inhibition In Breast Cancer
… and tumorigenesis. The crucial role of the CDK4/6-Cyclin D pathway has led to the development and FDA approval (palbociclib, ribociclib) of CDK4/6 inhibitors for the treatment of advanced estrogen receptor positive breast cancer. However, three major clinical challenges remain: i) adverse …
-
Mathematical Modeling of Therapies for MCF7 Breast Cancer Cells
… days. In addition to palbociclib, we add another Cdk4/6 inhibitor to the model, abemaciclib, which can induce apoptosis at high concentrations. Then the model can match the effects of abemaciclib treatment at two different doses and also capture the apoptosis effects induced by abemaciclib. After …
-
Impact of Cyclin-Dependent Kinase 4 and 6 Inhibitors on Chemotherapy Utilization and Overall Survival in Women with HR+/HER2– Metastatic Breast Cancer in the United States
… the impact of cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor therapy class, introduced in 2015, on early chemotherapy utilization in an older population of patients with HR+/HER2– MBC in the United States (US). Methods: Using an interrupted time series design, patients with a confirmed …
-
Overcoming Resistance to CDK4/6-targeted Therapy Using JAK2/STAT3 Inhibitor in Triple-Negative Breast Cancer
… and metastasis. Cyclin-dependent kinase 4 and 6 (CDK4/6) are major cell cycle regulators that control G1 to S phase transition and aberrant hyperactivation of the CDK4/6 pathway results in uncontrolled cell proliferation. Although three CDK4/6 inhibitors (CDK4/6is) have achieved clinical benefits …
-
A SEARCH FOR EPIGENETIC VULNERABILITIES OF AML CELLS PERFORMED BY A CDK INHIBITOR¿BASED CRISPR SCREENING
… of the cell cycle through sub-optimal doses of CDK4/6 inhibitors reprograms the chromatin landscape of fast-cycling AML cells resistant to LSD1 inhibition, rendering them more similar to slow-cycling counterparts that are intrinsically sensitive to LSD1 inhibition. This finding suggested that …
-
Simultaneous Targeting of CDK4/6 and BETs is Independent of RB Status in Osteosarcoma
… (MYC, RAD21) and cell cycle regulators (CDKN2A, CDK4/6), pointing to CDK4/6 inhibitors (CDK4/6i), like palbociclib and abemaciclib, as promising therapeutic strategies. However, monotherapy often fails, highlighting the need for effective combination approaches. While functional RB has …
-
Combined Inhibition of Ddr1 and Cdk4/6 Induces Synergistic Effects In Er-Positive, Her2-Negative Breast Cancer With Pik3Ca/Akt1 Mutations
<p><strong>COMBINED INHIBITION OF DDR1 AND CDK4/6 INDUCES SYNERGISTIC EFFECTS IN ER-POSITIVE, HER2-NEGATIVE BREAST CANCER WITH <em>PIK3CA/AKT1</em> MUTATIONS</strong></p> <p>Maryam Shariati, M.S. Advisory Professor: Funda Meric-Bernstam, M.D.</p> <p>Molecular alterations in the phosphatidylinositol …
-
A Compendium of Genetic Drivers for Oesophageal Adenocarcinoma defines Prognostic and Therapeutic Biomarkers for use in the Clinic
… 50% of OACs contained sensitizing events for CDK4 and CDK6 inhibitors, which were highly correlated with clinically relevant sensitivity in a panel of OAC cell lines and organoids. In a smaller panel of OACs we also saw evidence for specificity of BET inhibitor efficacy to MYC amplified OACs, …
-
Genome-scale Precision Proteomics Identifies Cancer Signaling Networks and Therapeutic Vulnerabilities
… actionable lesions. Recent success targeting CDK4/6 and MEK in RAS mutant adult cancers led our collaborator Dr. Dyer’s group to test this approach for rhabdomyosarcoma. They achieved synergistic killing of RAS mutant rhabdomyosarcoma tumor cells by combining MEK and CDK4/6 inhibitors in …